Protocol AP: Diabetic Retinopathy Research Study

Clinical Trial Title Protocol AP-comboPDR: A randomized clinical trial evaluating combination therapy with Faricimab + PRP versus vitrectomy + endolaser for the treatment of proliferative diabetic retinopathy

National Clinical Trial Number: NCT06790784

Clinical Trial Protocol Description:

This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either a combination of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up, and cost.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

Are 18 years of age or older.
Have Type 1 or Type 2 diabetes.
Have diabetic eye disease that requires treatment.
Have vision that is 20/100 or better in the study eye.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.